Skip to main content

Advertisement

Table 3 Summary of the most common adverse events

From: Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR

  PCG arm (N = 43) (%) PC arm (N = 43) (%) P-value for all grade AE
All grade Gr 3 Gr 4 Gr 5 All grade Gr 3 Gr 4 Gr 5
Patients with ≥ 1 AE (Gr3/4/5) 10 (23)     12 (28)     0.244
aRash 27 (63)     2 (5)     <0.001
aPruritis 13 (37)     4 (9)     0.012
Myalgia 25 (58)     28 (65)     0.506
Neuropathy 21 (49)     25 (58)     0.387
Alopecia 24 (56)     21 (49)     0.517
Anorexia 15 (35)     18 (42)     0.506
Cough 16 (37)     11 (26)     0.245
Nausea 13 (30)     8 (19)     0.209
Fatigue 10 (23)     10 (23)     1.000
Dyspepsia 6 (14)     7 (16)     0.763
Constipation 6 (14)     6 (14)     1.000
Diarrhea 5 (12)     5 (12) 1 (2)    1.000
Chest pain 5 (12)     5 (12)     1.000
General weakness 5 (12) 1 (2)    5 (12)     1.000
Infection 6 (14) 4 (9)   2 (5) 3 (7) 3 (7)    0.483
TE event 1 (2)     2 (5)   1 (2) 1 (2) 0.571
Neutropenia 10 (23)   2 (5)   7 (16) 3 (7) 1 (2)   0.660
Febrile neutropenia 0     1 (2)     1.000
Anemia 35 (81) 1 (2)    34 (79) 1 (2)    0.787
Thrombocytopenia 9 (21)     8 (19) 1 (2)    0.787
Leucopenia 6 (14) 2 (5)    6 (14)   1 (2)   1.000
Increased LFT 15 (35) 1 (2)    11 (26)     0.348
  1. AE adverse event; Gr grade; N number, LFT liver function test
  2. asignificant difference between two groups